Journal article
High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
SP Keam, H Halse, T Nguyen, M Wang, N Van Kooten Losio, C Mitchell, F Caramia, DJ Byrne, S Haupt, G Ryland, PK Darcy, S Sandhu, P Blombery, Y Haupt, SG Williams, PJ Neeson
Journal for Immunotherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020
Abstract
Background Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment and is commonly immune excluded with few infiltrative lymphocytes and low levels of immune activation. High-dose radiation has been demonstrated to stimulate the immune system in various human solid tumors. We hypothesized that localized radiation therapy, in the form of high dose-rate brachytherapy (HDRBT), would overcome immune suppression in PCa. Methods To investigate whether HDRBT altered prostate immune context, we analyzed preradiation versus postradiation human tissue from a cohort of 24 patients with localized PCa that received HDRBT as primary treatment (RadBank cohort). We performed Nanostring imm..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
This study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid), and an NHMRC Program Grant.